TR199902442T2 - �eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler. - Google Patents
�eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler.Info
- Publication number
- TR199902442T2 TR199902442T2 TR1999/02442T TR9902442T TR199902442T2 TR 199902442 T2 TR199902442 T2 TR 199902442T2 TR 1999/02442 T TR1999/02442 T TR 1999/02442T TR 9902442 T TR9902442 T TR 9902442T TR 199902442 T2 TR199902442 T2 TR 199902442T2
- Authority
- TR
- Turkey
- Prior art keywords
- treatment
- compounds
- agonists
- swelling
- levels
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3676097P | 1997-01-28 | 1997-01-28 | |
GBGB9705041.3A GB9705041D0 (en) | 1997-03-12 | 1997-03-12 | Thiazole benzenesulfonamides as selective B3 agonists for the treatment of diabetes and obesity |
Publications (1)
Publication Number | Publication Date |
---|---|
TR199902442T2 true TR199902442T2 (xx) | 2000-07-21 |
Family
ID=26311166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TR1999/02442T TR199902442T2 (xx) | 1997-01-28 | 1998-01-23 | �eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler. |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0968209A1 (fr) |
JP (1) | JP2001509166A (fr) |
KR (1) | KR20000070568A (fr) |
CN (1) | CN1251099A (fr) |
AR (1) | AR011092A1 (fr) |
AU (1) | AU728812B2 (fr) |
BG (1) | BG103686A (fr) |
BR (1) | BR9807096A (fr) |
CA (1) | CA2278739A1 (fr) |
EA (1) | EA199900692A1 (fr) |
EE (1) | EE9900328A (fr) |
HR (1) | HRP980044A2 (fr) |
HU (1) | HUP0002053A3 (fr) |
ID (1) | ID22273A (fr) |
IL (1) | IL131130A0 (fr) |
IS (1) | IS5131A (fr) |
NO (1) | NO993646L (fr) |
PE (1) | PE52299A1 (fr) |
PL (1) | PL334833A1 (fr) |
SK (1) | SK100099A3 (fr) |
TR (1) | TR199902442T2 (fr) |
WO (1) | WO1998032753A1 (fr) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
JP2003520226A (ja) | 2000-01-21 | 2003-07-02 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼ−iv阻害剤および抗糖尿病薬剤を含む組合せ物 |
EP1258253A1 (fr) * | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Nouveaux remedes et utilisation d'un agoniste beta3 |
TR200401359T4 (tr) | 2000-03-31 | 2004-08-23 | Pfizer Products Inc. | İkame edilmiş piridinlerin hazırlanmasına yönelik işlem |
JP4988128B2 (ja) * | 2000-07-13 | 2012-08-01 | イーライ リリー アンド カンパニー | β3アドレナリン作動性アゴニスト |
US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
US6537994B2 (en) | 2000-07-17 | 2003-03-25 | Wyeth | Heterocyclic β3 adrenergic receptor agonists |
US6410734B1 (en) | 2000-07-17 | 2002-06-25 | Wyeth | 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists |
US6498170B2 (en) * | 2000-07-17 | 2002-12-24 | Wyeth | Cyclamine sulfonamides as β-3 adrenergic receptor agonists |
US6465501B2 (en) | 2000-07-17 | 2002-10-15 | Wyeth | Azolidines as β3 adrenergic receptor agonists |
US6369232B1 (en) * | 2000-08-15 | 2002-04-09 | Hoffmann-La Roche Inc. | Tetrazolyl-phenyl acetamide glucokinase activators |
CA2421594A1 (fr) | 2000-11-10 | 2002-05-16 | John Arnold Werner | Agonistes du recepteur beta-3 d'oxindole 3-substitue |
AU2002221080A1 (en) * | 2000-12-08 | 2002-06-18 | Masami Kusaka | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparingthe same and use thereof |
AR035605A1 (es) | 2000-12-11 | 2004-06-16 | Bayer Corp | Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores |
AR035858A1 (es) | 2001-04-23 | 2004-07-21 | Bayer Corp | Derivados de cromano 2,6-sustituidos,composiciones farmaceuticas,uso de dichos derivados para la manufactura de medicamentos utiles como agonistas adrenorreceptores beta-3 |
ES2255621T3 (es) * | 2001-06-22 | 2006-07-01 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
DE60211199T2 (de) | 2001-08-14 | 2007-02-01 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindol-beta-3-agonisten |
ES2272749T3 (es) | 2001-08-14 | 2007-05-01 | Eli Lilly And Company | Derivados de indol como agonistas beta-3 adrenergicos para el tratamiento de diabetes tipo 2. |
CA2463441A1 (fr) * | 2001-10-12 | 2003-05-08 | Bayer Pharmaceuticals Corporation | Heterocycles utiles pour le traitement de l'obesite |
JP2005518357A (ja) | 2001-11-20 | 2005-06-23 | イーライ・リリー・アンド・カンパニー | ベータ3アドレナリンアゴニスト |
ATE297925T1 (de) | 2001-11-20 | 2005-07-15 | Lilly Co Eli | 3-substituierte oxindol beta 3 agonisten |
US7009060B2 (en) | 2002-01-11 | 2006-03-07 | Eli Lilly And Company | 2-oxo-benzimidazolyl substituted ethanolamine derivatives and their use as β3 agonists |
US6872724B2 (en) | 2002-07-24 | 2005-03-29 | Merck & Co., Inc. | Polymorphs with tyrosine kinase activity |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
EP2305352A1 (fr) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques |
WO2006132196A1 (fr) * | 2005-06-08 | 2006-12-14 | Asahi Kasei Pharma Corporation | PRODUIT PHARMACEUTIQUE ORIGINAL COMPRENANT UN AGONISTE β3 |
PE20070458A1 (es) | 2005-09-14 | 2007-07-05 | Takeda Pharmaceutical | Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa |
EP1940842B1 (fr) | 2005-09-29 | 2012-05-30 | Merck Sharp & Dohme Corp. | Dérivés acylés de spiropipéridine en tant que modulateurs du récepteur de la mélanocortine-4 |
EP1937264B1 (fr) * | 2005-10-04 | 2011-06-08 | Merck Sharp & Dohme Corp. | Polytherapie destinee au traitement de la pollakiurie, de la miction imperieuse et de l'incontinence urinaire |
EP2698157B1 (fr) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3239170B1 (fr) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
EP3241839B1 (fr) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
CA2741125A1 (fr) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Nouveaux derives de benzimidazole cycliques utiles comme agents anti-diabetiques |
WO2010051206A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques |
WO2011041293A1 (fr) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Dérivés pyrazolo [1, 5a] pyrimidines comme inhibiteurs de kinase 1 régulatrice de signal d'apoptose |
WO2011097079A1 (fr) | 2010-02-03 | 2011-08-11 | Takeda Pharmaceutical Company Limited | Inhibiteurs de kinase 1 régulant le signal d'apoptose |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP2677869B1 (fr) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
ES2394349B1 (es) | 2012-08-29 | 2013-11-04 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar |
US9784726B2 (en) | 2013-01-08 | 2017-10-10 | Atrogi Ab | Screening method, a kit, a method of treatment and a compound for use in a method of treatment |
AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
CA2905435A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
WO2015051496A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
EP3551176A4 (fr) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
EP3558298A4 (fr) | 2016-12-20 | 2020-08-05 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
GB201714736D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714745D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714734D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB201714740D0 (en) | 2017-09-13 | 2017-10-25 | Atrogi Ab | New compounds and uses |
GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0091749A3 (fr) * | 1982-04-08 | 1984-12-05 | Beecham Group Plc | Dérivés de l'éthanolamine, procédé pour leur préparation et compositions pharmaceutiques les contenant |
US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
IL113410A (en) * | 1994-04-26 | 1999-11-30 | Merck & Co Inc | Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them |
-
1998
- 1998-01-23 ID IDW990755A patent/ID22273A/id unknown
- 1998-01-23 BR BR9807096-7A patent/BR9807096A/pt not_active IP Right Cessation
- 1998-01-23 EE EEP199900328A patent/EE9900328A/xx unknown
- 1998-01-23 SK SK1000-99A patent/SK100099A3/sk unknown
- 1998-01-23 TR TR1999/02442T patent/TR199902442T2/xx unknown
- 1998-01-23 AU AU60384/98A patent/AU728812B2/en not_active Ceased
- 1998-01-23 CA CA002278739A patent/CA2278739A1/fr not_active Abandoned
- 1998-01-23 IL IL13113098A patent/IL131130A0/xx unknown
- 1998-01-23 EP EP98903677A patent/EP0968209A1/fr not_active Withdrawn
- 1998-01-23 CN CN98803585A patent/CN1251099A/zh active Pending
- 1998-01-23 PL PL98334833A patent/PL334833A1/xx unknown
- 1998-01-23 HU HU0002053A patent/HUP0002053A3/hu unknown
- 1998-01-23 WO PCT/US1998/001317 patent/WO1998032753A1/fr not_active Application Discontinuation
- 1998-01-23 KR KR1019997006814A patent/KR20000070568A/ko not_active Application Discontinuation
- 1998-01-23 EA EA199900692A patent/EA199900692A1/ru unknown
- 1998-01-23 JP JP53214898A patent/JP2001509166A/ja active Pending
- 1998-01-27 AR ARP980100357A patent/AR011092A1/es unknown
- 1998-01-28 HR HR9705041.3A patent/HRP980044A2/hr not_active Application Discontinuation
- 1998-01-28 PE PE1998000064A patent/PE52299A1/es not_active Application Discontinuation
-
1999
- 1999-07-23 IS IS5131A patent/IS5131A/is unknown
- 1999-07-27 NO NO993646A patent/NO993646L/no not_active Application Discontinuation
- 1999-08-24 BG BG103686A patent/BG103686A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
BR9807096A (pt) | 2000-04-18 |
WO1998032753A1 (fr) | 1998-07-30 |
IS5131A (is) | 1999-07-23 |
HUP0002053A2 (hu) | 2001-08-28 |
ID22273A (id) | 1999-09-23 |
EE9900328A (et) | 2000-02-15 |
PE52299A1 (es) | 1999-05-26 |
NO993646L (no) | 1999-09-27 |
CA2278739A1 (fr) | 1998-07-30 |
AR011092A1 (es) | 2000-08-02 |
PL334833A1 (en) | 2000-03-27 |
EA199900692A1 (ru) | 2000-02-28 |
HRP980044A2 (en) | 1998-10-31 |
HUP0002053A3 (en) | 2001-09-28 |
JP2001509166A (ja) | 2001-07-10 |
AU6038498A (en) | 1998-08-18 |
BG103686A (bg) | 2000-06-30 |
NO993646D0 (no) | 1999-07-27 |
AU728812B2 (en) | 2001-01-18 |
EP0968209A1 (fr) | 2000-01-05 |
CN1251099A (zh) | 2000-04-19 |
IL131130A0 (en) | 2001-01-28 |
KR20000070568A (ko) | 2000-11-25 |
SK100099A3 (en) | 2000-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TR199902442T2 (xx) | �eker ve �i�manl�k tedavisinde �3 agonistleri olarak tiazol benzens�lfonamidler. | |
ES2104259T3 (es) | Fenilsulfonamidas sustituidas como agonistas beta3 selectivos para el tratamiento de la diabetes y la obesidad. | |
MXPA03000308A (es) | Agonistas beta3 adrenergicos. | |
TR200000481T2 (tr) | N-Alkonoilfenilalenin türevleri. | |
WO2005097051A3 (fr) | Colorants a base de sulfide | |
NO964548L (no) | Substituerte sulfonamider som selektive 3 agonister for behandling av diabetes og fedme | |
BRPI0514060A (pt) | combinação de bupropion e um segundo composto para acarretar a perda de peso | |
ATE260910T1 (de) | 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester- transfer-proteins (ctep) | |
Allardyce et al. | The last piece in the cellulase puzzle: the characterisation of β-glucosidase from the herbivorous gecarcinid land crab Gecarcoidea natalis | |
DK0634414T3 (da) | Isolering og struktur af spongistatin 5,7,8 og 9 og deres anvendelse som antitumormidler | |
DE60023660D1 (de) | Antizymmodulatoren sowie deren verwendung | |
KR870008025A (ko) | 정상 인체 결장 세포로 부터 인체조직 푸라스미노겐 활성화인자 | |
Malik et al. | Haloferax sulfurifontis GUMFAZ2 producing xylanase‐free cellulase retrieved from Haliclona sp. inhabiting rocky shore of Anjuna, Goa‐India | |
BRPI0418462A (pt) | derivados de tetrahidroisoquinolina e terahidrobenzazepina como inibidores igf-1r | |
Hsieh et al. | Regulation of basal and luminal cell-specific cytokeratin expression in rat accessory sex organs. Evidence for a new class of androgen-repressed genes and insight into their pairwise control. | |
Macris et al. | Production and cross-synergistic action of cellulolytic enzymes from certain fungal mutants grown on cotton and straw | |
Pisa et al. | Agrowastes as Feedstock for the Production of Endo-β-Xylanase from Cohnella sp. Strain AR92 | |
Xu et al. | Purification and characterization of an endo-1, 4-β-D glucanase from the cellulolytic system of the wood-boring marine mollusk Lyrodus pedicellatus (Bivalvia: Teredinidae) | |
ECSP982387A (es) | Benceno sulfonamidas de tiazol como agonistas selectivos para el tratamiento de diabetes y obesidad | |
Cassuto et al. | The thermogenic role of the liver in the heat-acclimated hamster (Mesocricetus auratus) | |
Ohnishi et al. | Fluorescence histochemical studies of adrenergic nerve fibres and serotonin containing mast cells of the knee joint synovial membrane in normal and experimental arthritic rats | |
TOMONAGA et al. | Histochemical Study on Lactic Dehydrogenase Isozyme (1) On its Method and the Distribution in Various Tissues | |
Mateescu et al. | Effect of some enzymes as additives in piglet diet on their growth performances. | |
Rojas et al. | Growth and destructive potential of Psiloteredo healdi(Bivalvia: Teredinidae) present in Ana Maria Campos Mangrove. Tablazo Bay, Lake Maracaibo, Venezuela. | |
Kaminer | Contractile responses in the presence of electron donors and acceptors |